Investors
Investment Opportunity
Cymatrax is seeking investment to scale its SaaS platform, expand into new markets (streaming, healthcare), and continue R&D for clinical applications.
Investment will be used to accelerate product development, expand the sales team, and initiate large-scale clinical trials
-
Currently raising $1M at $10M valuation
-
$250K raised to date
Cymatrax Revenue Plan
Monthly subscriptions for small, medium and enterprise users ($0-$12.99 per month assessed at number of files filtered) is currently being QC’d, as well as streaming media will range from $0.03-0.05 per month (plug in).
-
Initial 2 year licensing $3k-80k,
-
Licensing with royalties will be judged upon distribution expectations
-
Webite for Retail Users is already available on at https://cymatrax.com/, as a monthly subscription service, Freemium, Gold and Platinum
Massive Digital Audio Market
With over 5 billion people listening to digital audio daily, Cymatrax is targeting a broad spectrum of applications, from entertainment to health.
ncreasing awareness around mental health and the role of sound therapy offers significant market potential. Additionally, the integration into consumer devices (e.g., headphones, speakers) expands commercial applications.
Shaping the Future of Human Communication
With Cymatrax’s patented optimization technology, we are uniquely positioned to lead in this expanding global market, delivering measurable results for both users and stakeholders.
Cymatrax Optimizes Seven Target Frequencies, Including 432Hz
Cymatic resonance spatially condenses neurotransmitters into coherent centerpoints
Enhanced synaptic efficiency with amyloid obstruction bypass
Optimized signal propagation for PTSD and Autism-friendly learning aids
Conventional Synaptic Transmission
Stochastic neurotransmitter diffusion across synaptic cleft
Signal fidelity compromised by intracellular amyloid aggregates
Disrupted axonal conduction limits ADHD learning tools effectiveness
Conventional vs Cymatrax 432 Hz-Enhanced Synaptic Dynamics
Our patented brain optimization technology uses precise 432Hz (and six others) cymatic resonance patterns to transform stochastic neurotransmitter diffusion into coherent, focused delivery systems for enhanced online training for neurodiverse learners, podcast audio enhancement, and PTSD and Autism-friendly learning aids.
Leading the Way in Brain Optimization Technology
Our patented brain optimization technology restructures digital audio frequencies to reduce stress, boost focus, and improve cognitive performance. By filtering harmful frequency distortions, our solution creates a healthier listening experience that enhances productivity, learning retention, and overall mental well-being.
Built on scientifically validated research from leading institutions including Johns Hopkins, Mayo Clinic, MIT, and Oxford Neurological Institute, Cymatrax is more than audio enhancement—it’s a cognitive revolution.
The Cymatrax Journey - From Vision to Patented Innovation
From an ambitious vision to a patented innovation, Cymatrax’s journey began with the challenge of creating acoustic base code few developers in the world could master.
Backed by Science
Collaborating with leading institutions like Johns Hopkins, MIT, and Oxford, we proved how targeted frequencies can optimize brain function, while removing harmful noise found in 99.9% of digital audio.
Patented for Global Impact
From podcasts to medical trials, our patented brain optimization technology is ready to transform streaming platforms, corporate training, and neurological therapies worldwide.
From Vision to Innovation
What began as a bold idea—to make all digital audio healthier—required finding one of the rare few in the world capable of writing acoustic base code. After reviewing over 1,200 developers, the right partner brought our vision to life.
Get in Touch
Be part of the next wave in neuroscience-powered audio innovation.
Partner with Cymatrax to bring brain optimization technology to global markets.